SCHEMBL1020098

SCHEMBL1020098

O=S(=O)(NCCCNc1nc(Cc2cccc(F)c2)ns1)c1cccs1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.44
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PKM P14618 2/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTR2A P28223 4/20 0.39
HTR7 P34969 4/20 0.39
HTR6 P50406 4/20 0.39
DRD2 P14416 3/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019647 0.94 CYP2D6 (0.47) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1019761 0.89 NPY5R (0.46) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1019495 0.89 NPY5R (0.44) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1023622 0.88 NPY5R (0.51) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1020198 0.87 PKM (0.57) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1020941 0.86 NPY5R (0.42) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1021038 0.83 TSHR (0.47) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1019556 0.83 NPY5R (0.46) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1019823 0.83 CYP2D6 (0.50) NPY5RCYP2D6CYP2C9CYP2C19PKM
SCHEMBL1021488 0.83 NPY5R (0.48) NPY5RCYP2D6CYP2C9CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP NPY5R 4220/4885CYP2D6 4262/4885CYP2C9 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.